

University of Miami/Jackson Memorial Hospital (Main)
ANTIBIOTIC SUSCEPTIBILITY REPORT July - December 2013

Data include 1st isolate from patient (JMH Central)

T.J. Cleary, PhD (305 585-7851)

CLSI M100-S23, 2013 breakpoints

GRAM-NEGATIVE ISOLATES	No.	Percent susceptible														
		AMS	P/T	CZ	FOX	CRO	CAZ	FEP	ERT	MER	AN	GM	TOB	LVX	SXT	TET
Escherichia coli	1455	44	92	75	86	85	91	97	99	99	99	84	84	62	55	57
Citrobacter freundii	30	/	70	/	/	/	/	99	99	99	99	90	87	73	63	63
Citrobacter koseri	48	/	99	98	94	98	99	99	98	99	99	99	99	99	99	98
Klebsiella pneumoniae	545	66	82	/	90	81	81	93	99	97	98	85	82	81	74	71
Enterobacter aerogenes	79	/	81	/	/	/	81	98	96	96	99	95	96	95	98	91
Enterobacter cloacae	186	/	82	/	/	/	77	96	97	99	99	97	97	94	90	89
Serratia marcescens	78	/	99	/	/	/	94	97	99	96	99	94	91	82	95	53
Proteus mirabilis	252	84	98	61	92	93	96	98	98	98	99	92	93	86	79	/
Morganella morganii	67	/	97	/	/	/	91	99	99	99	98	78	88	70	56	/
Providencia stuartii	20	/	95	/	/	70	85	90	95	99	99	/	/	40	60	/
Pseudomonas aeruginosa	424	/	82	/	/	/	81	82	/	72	96	81	92	66	/	/
Acinetobacter baumannii	139	65	48	/	/	/	/	/	/	54	86	54	69	48	52	51
Stenotrophomonas maltophilia	102	/	/	/	/	/	/	/	/	/	/	/	/	91	87	/

AMS	AMP/SULBACTAM
AN	AMIKACIN
CAZ	CEFTAZIDIME
CEF	CTX or CRO
CIP	CIPROFLOXACIN
CLN	CLINDAMYCIN
CRO	CEFTRIAXONE
CTX	CEFOTAXIME
CZ	CEFAZOLIN
ERT	ERTAPENEM
ERY	ERYTHROMYCIN
FEP	CEFEPIME
FOX	CEFOXITIN
GM	GENTAMICIN
IMP	IMIPENEM
LVX	LEVOFLOXACIN
LZD	LINEZOLID
OX	OXACILLIN
PEN	PENICILLIN
P/T	PIP/TAZOBACTAM
RIF	RIFAMPIN
SYN	QUINUPRIS/DALFO
SXT	TRIMETH/SULFA
TE	TETRACYCLINE
TOB	TOBRAMYCIN
VA	VANCOMYCIN

(/) slash indicates that the drug is clinically ineffective or <20% susceptible (Sanford Guide to Antimicrobial Therapy, 2013)

GRAM-POSITIVE ISOLATES	No.	Percent susceptible													
		PEN	OX	CZ	CEF	CLN	ERY	GM	LVX	RIF	TE	SYN	LZD	VA	SXT
Enterococcus faecalis	373	97	/	/	/	/	/	/	76	/	22	/	100	97	/
Enterococcus faecium	87	15	/	/	/	/	/	/	/	/	19	92	100	34	/
Staph aureus MRSA ^a	485	0	0	0	0	63	10	94	31	99	89	89	100	100	92
Staph aureus MSSA ^a	433	2	100	100	100	77	62	98	89	99	89	79	100	100	97
Staphylococcus epidermidis ^a	225	1	26	26	/	58	32	70	/	96	83	/	100	100	38
Staphylococcus haemolyticus ^a	66	0	35	35	/	62	14	72	/	97	57	/	100	97	62
Staphylococcus hominis ^a	48	0	28	28	/	46	19	87	/	92	70	/	100	100	53
Streptococcus agalactiae	82	100	/	/	/	84	63	/	98	/	/	99	100	99	/
Streptococcus pneumoniae ^{b,c}	32	81	/	/	81	73	55	/	100	/	/	/	100	100	60

- (a) S. aureus and coagulase-negative staph (CNS) resistant to oxacillin are resistant to penicillins, cephalosporins, and carbapenems overall MRSA = 53% of all Staphylococcus aureus isolates
- (b) Streptococcus pneumoniae: 26 isolates (81%) were susceptible to penicillin (MIC \leq 2.0 ug/ml) by CLSI parenteral breakpoints for non-meningeal infections
- (c) Streptococcus pneumoniae: 26 isolates (81%) were susceptible to cefotaxime or ceftriaxone (MIC \leq 1.0 ug/ml) by CLSI parenteral breakpoints for non-meningeal infections